16results about How to "Achieve targeted release" patented technology

The application provides a preparation method of astaxanthin cordyceps militaris fine tablets, comprising the following steps: subjecting cordyceps militaris fruiting bodies to supercritical CO2 extraction treatment to separate a cordyceps militaris terpene component; mixing Haematococcus pluvialis powder and edible vegetable oil, adding the cordyceps militaris terpene component and rosemary extract, and cooling and forming to obtain an astaxanthin-cordyceps militaris terpene blend; crushing the residue after extraction, adding purified water and a composite enzyme preparation to perform enzymolysis to obtain an enzymolysis liquid; adding a chitosan quaternary ammonium salt solution, centrifuging after flocculation, vacuum drying, and crushing to obtain cordyceps militaris active powder; mixing and granulating raw materials to obtain granulation particles; uniformly mixing the granulation particles with xylitol and microcrystalline cellulose, and pressing into tablets; and placing the tablets in a coating machine for coating. The application realizes efficient retention of active ingredients, improvement of safety and stability of product quality through the cooperation of multiple technologies such as supercritical CO2 extraction, enzymolysis flocculation, low-temperature fluidized bed granulation and hot melt coating.

The application discloses a special feed for fattening pigs rich in functional amino acids, which comprises the following components in parts by weight: a core functional amino acid composition 3-5 parts, a low-soybean meal multi-protein matrix 60-70 parts, a nutrition synergistic component 20-25 parts, an anti-nutritional factor degradation agent 1-2 parts, and a micro-ecological and plant extract component 1-2 parts. A preparation method comprises the following steps: obtaining the low-soybean meal multi-protein matrix by pretreating raw materials; preparing the core functional amino acid microcapsule; mixing the basic materials and then performing low-temperature section granulation; after cooling, mixing the micro-ecological and plant extract component at low temperature; and finally screening and removing impurities and unqualified particles to obtain the finished product. The application optimizes the amino acid ratio and the preparation process, protects the activity of the amino acids, adapts to different growth stages of the fattening pigs, improves the growth performance and carcass quality, improves the raw material digestion rate, reduces nitrogen emission, and has strong applicability.

This invention belongs to the technical field of additive manufacturing technology and discloses an in-situ oxygen-controlled composite scraper and a laser selective melting device equipped with the in-situ oxygen-controlled composite scraper. The bottom of the composite scraper includes a second scraper (16), an air jet unit, and a first scraper (18) arranged sequentially along the powder spreading direction. It has an internal gas storage chamber (15) and a powder drop chamber (19). The first scraper is used to evenly spread the powder raw material to form an initial powder layer. The air jet unit performs in-situ oxidation treatment on the surface of the initial powder layer by spraying oxygen-containing gas. The second scraper is used to level and compact the powder layer after the in-situ oxidation treatment. This invention improves the composition and structure of the composite scraper and utilizes the overall cooperation of the first scraper, the air jet unit, and the second scraper to generate a synergistic mechanism of powder spreading, in-situ oxidation, and secondary compaction, breaking through the process limitation that it is difficult to construct oxide dispersion-strengthened structures in-situ during additive manufacturing.

The invention discloses a compound as well as a preparation method and application thereof, and belongs to the technical field of drug delivery systems and tumor targeted therapy. The compound as shown in the formula 1 is novel and unique in structure, can be used as an anti-melanoma prodrug compound, realizes targeted release and collaborative treatment of drugs (Devistat and TPEDCH) under laser irradiation, has a fluorescence imaging function, is used for monitoring the distribution and activation process of the drugs in tumor cells in real time, and has a good application prospect. The traditional Chinese medicine composition has excellent anti-melanoma effect and low toxic and side effects. Formula 1.

This invention discloses a modified children's dietary fiber based on microcapsule encapsulation and ultra-micro homogenization emulsification and its preparation method, which is prepared according to the following steps: (1) Raw material pretreatment: plant fiber is crushed; (2) Enzymatic modification: the fiber powder is prepared into a fiber suspension slurry, cellulase is added for enzymatic hydrolysis, and the modified fiber slurry is obtained after enzyme inactivation and cooling; (3) Composite wall material preparation: maltodextrin or whey protein and gum arabic are weighed, dissolved in deionized water, and natural antioxidants are added; (4) Homogenization emulsification and microcapsule encapsulation: the modified fiber slurry obtained in step (2) is dispersed in the wall material solution in step (3) as the core material, and homogenized using a two-stage gradient high pressure treatment. After homogenization, the product is obtained by spray drying or fluidized bed encapsulation and solidification. Through nanoscale reshaping and directional encapsulation, the rough taste of dietary fiber is completely eliminated, unpleasant flavors are masked, and natural antioxidants are used to improve the stability and intestinal bioavailability of the product.

The application discloses a feline panleukopenia virus, feline herpes virus and feline calicivirus yolk antibody preparation and a preparation method and application thereof. The feline triple yolk antibody preparation comprises a core material, and the core material comprises feline calicivirus yolk antibody, feline panleukopenia virus yolk antibody, feline herpes virus type 1 yolk antibody and probiotics. The application can produce specific neutralization to feline calicivirus, feline panleukopenia virus and feline herpes virus type 1, significantly reduces the infection rate and the severity of clinical symptoms, is stably released in the gastrointestinal tract after oral administration, the antibody activity retention rate is more than 90%, the probiotics synergistically regulate intestinal microecology, enhance the immune response of the body and improve the overall protection efficiency.

The application discloses an intestinal-targeted controlled-release microalgae pharmaceutical composition, which comprises a hydrophobic drug, a micellar material and microalgae, wherein the hydrophobic drug is first loaded on the micellar material to form a drug-loaded micelle, the solubility of the hydrophobic drug is improved, and the drug-loaded micelle solution penetrates into the interior of the microalgae cells through a passive water absorption process of dried microalgae instead of being attached to the surface of the microalgae. The natural cell wall of the microalgae itself is solid and acid-resistant, which is used as a first physical barrier to prevent the release of the hydrophobic drug in a gastric acid environment, and the effective concentration and residence time of the hydrophobic drug in the intestinal action site are significantly improved, so that the treatment effect is better, and the intestinal disease and kidney disease drug can be prepared.

The invention relates to the field of formula foods for special medical purposes, in particular to a functional nutritional supplement containing calcium beta-hydroxy-beta-methylbutyrate, which comprises the following raw materials in parts by mass: 2.6-7.7 parts of calcium beta-hydroxy-beta-methylbutyrate; 13.8 to 17.2 parts of compound amino acid; 56 to 78.5 parts of whey protein powder; 0.2 to 0.5 part of vitamin; 0.3 to 0.5 part of hydroxy citric acid; 4.9 to 5.5 parts of functional nano particles; 2.3 to 3 parts of a cyclodextrin inclusion compound; 0.9-1.2 parts of a rhizoma alismatis soup polysaccharide composition; 1-3 parts of inulin; 1-3 parts of lotus leaf pectin polysaccharide (LLP); 0.5 to 0.9 part of hydrophilic fumed silica; the functional nanoparticles, the cyclodextrin inclusion compound, the rhizoma alismatis decoction polysaccharide composition and the calcium beta-hydroxy-beta-methylbutyrate have a synergistic effect, anabolism is enhanced, catabolism is inhibited, the sarcopenia is effectively improved, and the composition has a wide application prospect.

The application provides a low-pressure drug-loaded balloon catheter system for preoperative treatment of abdominal aortic aneurysm endovascular repair and a pre-treatment method, which comprises a catheter main body, a segmented balloon structure is arranged at the distal end of the catheter main body, a drug-loaded coating structure for realizing biological remodeling of the abdominal aortic aneurysm lesion vessel wall is arranged on the outer surface of the segmented balloon structure, the drug-loaded coating structure releases active drugs for inhibiting the pathological progression of abdominal aortic aneurysm under the action of blood flow, a pressure control system in communication with the segmented balloon structure is arranged on the catheter main body, and the pressure control system is used for low-pressure inflation of the segmented balloon structure and adjustment of injection pressure and flow rate. The application improves the local drug delivery efficiency under the premise of ensuring operation safety through the synergistic design of structural design and drug delivery mechanism, and provides a new preoperative intervention strategy for the treatment of abdominal aortic aneurysm.

The invention discloses an intestinal targeting probiotic emulsion gel capsule and a preparation method thereof. The preparation method comprises the following steps: firstly, preparing an acidic water phase containing probiotics and cationic polysaccharide, and preparing an oil phase containing a hydrophobic solid particle emulsifier and edible oil; the oil phase and the water phase are emulsified at a high speed, and stable emulsion gel is formed on an oil-water interface by utilizing an electrostatic crosslinking effect between the cationic polysaccharide and solid particles; further, edible colloid is used as a shell, and the emulsion gel inner core is packaged through a micro-fluidic technology to prepare the emulsion gel capsule. The emulsion gel disclosed by the invention can effectively resist a gastric acid environment, protect the activity of probiotics and realize targeted release in intestinal tracts by digesting an oil phase through lipase. The capsule is completely made of safe materials approved by FDA, has good stability, machinability and biocompatibility, remarkably improves the oral delivery efficiency of probiotics, and is suitable for the field of functional food and pharmaceutical preparations.

This invention relates to the synergistic anticancer application of redox-responsive condensates (FFSSFF) for delivering jujube extract and 3-methyladenine. Specifically, this invention relates to the application of redox-responsive condensates in the preparation of targeted drug delivery products, wherein the targeted drug delivery products release drugs in response to glutathione. The active ingredients in the targeted drug delivery products are jujube extract and 3-methyladenine. This invention utilizes an FFSSFF carrier designed based on the LLPS principle, integrating redox-sensitive disulfide bond linkage modules to achieve spatiotemporally controlled drug delivery within a tumor tissue-specific microenvironment with high glutathione concentrations.

The invention relates to the technical field of cosmetics, and discloses bakuchiol salicylate and application thereof. The structural formula of the bakuchiol salicylate is as shown in formula I in the specification. According to the bakuchiol salicylate disclosed by the invention, two active molecules are integrated into a brand new chemical entity through a covalent ester bond, so that an easily oxidized phenolic hydroxyl group of bakuchiol and a strongly acidic carboxyl group of salicylic acid are effectively masked, the chemical stability is improved, the bakuchiol salicylate is difficult to oxidize and degrade, the skin irritation is greatly reduced, the lipophilicity is improved, and the skin care effect is good. Compared with simple physical compounding of bakuchiol and salicylic acid in the prior art, by means of the innovative prodrug design, the synergistic breakthrough of stability, safety and efficacy is successfully achieved, and the obvious synergistic effect is shown in the aspects of stability, oxidation resistance, inflammation resistance, whitening, aging resistance and the like.

This invention relates to the field of cementing materials technology, specifically disclosing a method for preparing a high-temperature cement stone strength degradation inhibitor and its application. The inhibitor is prepared using a two-step chemical modification method, based on a silane modifier, combined with active aluminum-containing materials, an activator, an alkaline modifier, and a solvent. Through steps such as silicate hydrolysis, surface grafting of the active aluminum-containing material, and secondary modification in an alkaline environment, a core-shell structured composite functional material is constructed. This material effectively inhibits cement stone strength degradation at temperatures of 180℃ and above, achieving a strength exceeding 40 MPa after 28 days of curing at 240℃. Furthermore, when added at a concentration of 10%, it affects the cement slurry thickening time by less than 65 minutes, while minimally interfering with the rheological properties of the cement slurry. It is suitable for high-temperature cementing operations in deep wells, ultra-deep wells, and thermal recovery wells. This invention combines high-temperature stability with construction friendliness, solving the technical challenges of shortening thickening time and increasing pumping risks associated with traditional aluminum-containing pozzolanic materials.

This invention provides a sustained-release microcapsule and its preparation method. The sustained-release microcapsule comprises: a porous carrier core; an active ingredient loaded within the pores of the porous carrier core; and a bilayer membrane structure covering the outer layer of the porous carrier core. The bilayer membrane structure includes an inner membrane and an outer membrane, with the inner membrane located between the porous carrier core and the outer membrane. The inner membrane is a pH-responsive protective layer that maintains structural stability in acidic environments and swells and disintegrates in weakly alkaline environments. The outer membrane is a flavor-regulating layer for the sustained-release flavor substances. The porous carrier core of this invention provides a large specific surface area and pore structure, effectively solving the problems of easy oxidation and stratification of the active ingredient. The inner membrane protects the active ingredient from degradation in the acidic environment of the stomach and rapidly swells and disintegrates in the weakly alkaline environment of the small intestine, significantly improving bioavailability. The outer membrane improves the palatability of the product.

This invention discloses a method for preparing soft-particle starter feed based on low-temperature curing and microencapsulation, belonging to the field of livestock and poultry feed preparation technology. The method includes basic raw material pretreatment, low-temperature curing, mixing and blending, soft-particle molding, drying and cooling, and screening and packaging steps. The core lies in employing a process of "low-temperature curing + double-layer microencapsulation + soft-particle molding," combined with an excipient system composed of modified chitosan, sodium alginate, and attapulgite solution. Low-temperature curing preserves heat-sensitive nutrients and kills harmful microorganisms; double-layer microencapsulation enables targeted release of core functional components, ensuring their activity; soft-particle molding balances palatability and intestinal protection; and the various components of the excipients synergistically improve feed stability, probiotic colonization rate, and digestibility.

The invention provides a sheep milk casein anticoagulant peptide as well as a preparation method and application thereof. The sheep milk casein anticoagulant peptide is VKETMVPK, VLPVPQK or EMPFPK. The invention solves the problems of low safety and high cost of the existing clinical anticoagulant drug; the high-valued utilization rate of sheep milk casein resource development is low; and the blank of the preparation technology of the sheep milk casein anticoagulant peptide is filled. The sheep milk casein inhibitory peptide provided by the invention has high safety, and avoids the defects of existing drug treatment; goat milk resource value is efficiently excavated, and resource waste is reduced; the technical blank is filled, and a systematic preparation system is established; the anticoagulant activity is clear and efficient, and the action mechanism is comprehensive; the application scene is wide and the market potential is great.